These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 8425019

  • 21. Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily.
    Cooley TP, Kunches LM, Saunders CA, Perkins CJ, Kelley SL, McLaren C, McCaffrey RP, Liebman HA.
    Rev Infect Dis; 1990; 12 Suppl 5():S552-60. PubMed ID: 1974727
    [Abstract] [Full Text] [Related]

  • 22. Use of didanosine in zidovudine-intolerant patients infected with human immunodeficiency virus.
    Nelson MR, Moyle GJ, Gazzard BG.
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S59-62. PubMed ID: 8093848
    [Abstract] [Full Text] [Related]

  • 23. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
    Montaner JS, Schechter MT, Rachlis A, Gill J, Beaulieu R, Tsoukas C, Raboud J, Cameron B, Salomon H, Dunkle L, Smaldone L, Wainberg MA.
    Ann Intern Med; 1995 Oct 15; 123(8):561-71. PubMed ID: 7677296
    [Abstract] [Full Text] [Related]

  • 24. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.
    Abrams DI, Goldman AI, Launer C, Korvick JA, Neaton JD, Crane LR, Grodesky M, Wakefield S, Muth K, Kornegay S.
    N Engl J Med; 1994 Mar 10; 330(10):657-62. PubMed ID: 7906384
    [Abstract] [Full Text] [Related]

  • 25. New developments in the clinical use of didanosine.
    Kahn J.
    J Acquir Immune Defic Syndr (1988); 1993 Mar 10; 6 Suppl 1():S47-50. PubMed ID: 8426301
    [Abstract] [Full Text] [Related]

  • 26. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
    Englund JA, Baker CJ, Raskino C, McKinney RE, Petrie B, Fowler MG, Pearson D, Gershon A, McSherry GD, Abrams EJ, Schliozberg J, Sullivan JL.
    N Engl J Med; 1997 Jun 12; 336(24):1704-12. PubMed ID: 9182213
    [Abstract] [Full Text] [Related]

  • 27. Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV.
    Mauss S, Adams O, Willers R, Jablonowski H.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr 15; 11(5):469-77. PubMed ID: 8605592
    [Abstract] [Full Text] [Related]

  • 28. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
    Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC.
    N Engl J Med; 1996 Oct 10; 335(15):1081-90. PubMed ID: 8813038
    [Abstract] [Full Text] [Related]

  • 29. The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. Alpha International Coordinating Committee.
    AIDS; 1996 Jul 10; 10(8):867-80. PubMed ID: 8828744
    [Abstract] [Full Text] [Related]

  • 30. A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease.
    Torres RA, Barr MR, McIntyre KI, Thornton JR, Shay WM, Feldman RD, George NJ, Britton DJ.
    Int J STD AIDS; 1995 Jul 10; 6(1):19-26. PubMed ID: 7727578
    [Abstract] [Full Text] [Related]

  • 31. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group.
    Bozzette SA, Kanouse DE, Duan N, Berry S, Richman DD.
    Antivir Ther; 1996 Jan 10; 1(1):21-32. PubMed ID: 11322256
    [Abstract] [Full Text] [Related]

  • 32. [Once-daily administration of didanosine in combination with anti-retroviral zidovudine in previously untreated patients].
    Reynes J, Montes B, Delmas B, Vendrell JP, Janbon F, Segondy M.
    Pathol Biol (Paris); 1997 May 10; 45(5):441-4. PubMed ID: 9296101
    [Abstract] [Full Text] [Related]

  • 33. [Anti-retroviral therapy of HIV-infection. With preliminary results of the Swiss postmarketing surveillance of zidovudine].
    Jost J, Lüthy R.
    Schweiz Med Wochenschr; 1991 Apr 20; 121(16):555-65. PubMed ID: 1904164
    [Abstract] [Full Text] [Related]

  • 34. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
    Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding PA, Crumpacker CS, Beall G.
    N Engl J Med; 1992 Aug 27; 327(9):581-7. PubMed ID: 1353607
    [Abstract] [Full Text] [Related]

  • 35. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.
    Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, Markowitz N, Reves R, Loveless MO, Crane L, Thompson M, Abrams D.
    N Engl J Med; 1996 Oct 10; 335(15):1099-106. PubMed ID: 8813040
    [Abstract] [Full Text] [Related]

  • 36. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
    Spruance SL, Pavia AT, Peterson D, Berry A, Pollard R, Patterson TF, Frank I, Remick SC, Thompson M, MacArthur RD, Morey GE, Ramirez-Ronda CH, Bernstein BM, Sweet DE, Crane L, Peterson EA, Pachucki CT, Green SL, Brand J, Rios A, Dunkle LM, Cross A, Brown MJ, Ingraham P, Gugliotti R, Schindzielorz AH, Smaldone L.
    Ann Intern Med; 1994 Mar 01; 120(5):360-8. PubMed ID: 7905722
    [Abstract] [Full Text] [Related]

  • 37. Didanosine dosed once daily is equivalent to twice daily dosing for patients on double or triple combination antiretroviral therapy. The AI454-147 Team.
    Kazatchkine MD, Van PN, Costagliola D, Mohammed AS, Ledeine JM, Troccaz M, Belec L.
    J Acquir Immune Defic Syndr; 2000 Aug 15; 24(5):418-24. PubMed ID: 11035612
    [Abstract] [Full Text] [Related]

  • 38. Phase I study of 2',3'-dideoxyinosine: experience with 19 patients at New York University Medical Center.
    Valentine FT, Seidlin M, Hochster H, Laverty M.
    Rev Infect Dis; 1990 Aug 15; 12 Suppl 5():S534-9. PubMed ID: 1974725
    [Abstract] [Full Text] [Related]

  • 39. Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.
    Faulds D, Brogden RN.
    Drugs; 1992 Jul 15; 44(1):94-116. PubMed ID: 1379914
    [Abstract] [Full Text] [Related]

  • 40. [Current developments in antiviral chemotherapy. Part 4: Foscarnet, zidovudine, didanosine].
    Stamminger T, Fleckenstein B.
    Fortschr Med; 1994 May 10; 112(13):190-1. PubMed ID: 8020860
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.